Key Takeaway Points in Phase III ALCYONE Trial for Multiple Myeloma

Maria-Victoria Mateos, MD, PhD, director of the Myeloma Unit at University Hospital of Salamanca-IBSAL Salamanca, Spain, discusses the key takeaways from the findings from the phase III ALCYONE trial for patients with multiple myeloma.

At a median follow-up of 28 months, data confirmed that the addition of daratumumab (Darzalex) to bortezomib, melphalan, and prednisone (VMP) is significantly superior to VMP alone, says Mateos. This is confirmed in terms of overall response rate, complete response rate, and progression-free survival (PFS).